Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study

Autor:	Canbaz H; Yıldırım Beyazıt University, Yenimahalle Training and Research Hospital, Emergency Service, Ankara, Turkey, İdiz UO; University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of General Surgery, İstanbul, Turkey, Cankar Dal H; University of Health Sciences Turkey, Ankara City Hospital, Clinic of Intensive Care Unit, Ankara, Turkey, Kaçıroğlu F; General Directorate of Health Services, Head of Tissue, Organ Transplantation and Dialysis Services Department, Ankara, Turkey, Taş S; General Directorate of Health Services, Department of Tissue, Organ Transplantation and Dialysis Services, Organ Transplantation Unit, Ankara, Turkey, Çubukçu HC; Ankara University Stem Cell Institute, Interdisciplinary Stem Cells and Regenerative Medicine, Ankara, Turkey, Beştemir A; İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Emergency Service, İstanbul, Turkey, Gülşen M; Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Pediatrics, Ankara, Turkey, Polat İT; Horasan State Hospital, Clinic of Anesthesiology and Reanimation, Ağrı, Turkey, Laloğlu A; Atatürk University Faculty of Dentistry, Department of Oral, Dental and Maxillofacial Radiology, Erzurum, Turkey, Tör İH; Erzurum City Hospital, Clinic of Anesthesiology and Reanimation, Erzurum, Turkey, Akkurt HE; Konya Numune Hospital, Clinic of Physical Medicine and Rehabilitation, Konya, Turkey, Ateş U; İstanbul Bilim University Faculty of Medicine, Department of Histology and Embryology, İstanbul, Turkey, Reisli İ; Necmettin Erbakan University Meram Medical Faculty Hospital, Department of Pediatric Immunology and Allergy, Konya, Turkey, Koç E; Gazi University Medical Faculty Hospital, Department of Pediatrics, Division of Neonatology, Ankara, Turkey, İnkaya AÇ; Hacettepe University Medical Faculty Hospital, Department of Infectious Diseases, Ankara, Turkey, Karakükçü M; Erciyes University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Kayseri, Turkey, Ceylan M; Atatürk University Medical Faculty Hospital, Department of Neurology, Erzurum, Turkey, Haznedaroğlu İC; Hacettepe University Medical Faculty Hospital, Department of Hematology, Ankara, Turkey, Akın H; Ege University Medical Faculty Hospital, Department of Medical Genetics, İzmir, Turkey
Jazyk:	angličtina
Zdroj:	Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2022 Dec 01; Vol. 39 (4), pp. 222-229. Date of Electronic Publication: 2022 Oct 17.
DOI:	10.4274/tjh.galenos.2022.2022.0103
Abstrakt:	Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC) therapy, which is one of those methods. The aim of our study is to evaluate the effect of MSC treatment applied together with standard treatments on survival. Materials and Methods: This retrospective case-control study evaluates the survival effect of MSC treatment administered to patients treated in intensive care after the development of ARDS due to COVID-19 between March 2020 and March 2021. The age, gender, comorbid disease status, APACHE II score, and overall and comorbidity-based survival rates were compared between patients who received standard medical treatment (SMT) and patients who received MSC treatment together with SMT. Results: There were 62 patients in the group receiving only SMT and 81 patients in the group receiving SMT and MSC. No difference was observed between the groups in terms of age, gender, presence of comorbid diseases, or APACHE II scores. There were also no differences according to Kaplan-Maier analysis for the survival statuses of the groups. There was no serious adverse effect due to MSC treatment among these patients. Conclusion: Our study presents the largest case series in the literature, and it was observed that MSC treatment may not significantly affect overall survival or comorbid disease-based survival, in contrast to many other studies in the literature. Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors. (©Copyright 2022 by Turkish Society of Hematology | Turkish Journal of Hematology, Published by Galenos Publishing House)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF